Dissociated non-steroidal glucocorticoid receptor modulators: An update on new compounds

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 3, 2008, Pages 339-352

  Schäcket, Heike ^a   Berger, Markus ^a   Hansson, Thomas G ^b   McKerrecher, Darren ^b   Rehwinkel, Hartmut ^a  

^a BAYER PHARMA AG   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Glucocorticoid receptor; Glucocorticoids; Selective glucocorticoid receptor agonists

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; AL 438; AMIDE; ANTIINFLAMMATORY AGENT; AZEPINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOTRIAZOLE DERIVATIVE; BI 101; BI 102; BI 115; BI 301; CYCLOBUTYLMETHYLPROPIONAMIDE DERIVATIVE; DIBENZO[B,F]PYRIDODIAZEPINE; DIBENZO[C,F]PYRIDOAZEPINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INDAN DERIVATIVE; INDOLE DERIVATIVE; LGD 5552; LIGAND; NON STEROIDAL GLUCOCORTICOID RECEPTOR MODULATOR; PHENYLAMINOPYRAZOLE AMIDE DERIVATIVE; PREDNISOLONE; PROPIONAMIDE DERIVATIVE; QUINOLINE DERIVATIVE; RU 24858; SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST; SULFONAMIDE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; NONHUMAN; RECEPTOR INTRINSIC ACTIVITY; REVIEW; TRANSACTIVATION;

EID: 42549123138     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.3.339     Document Type: Review

References (83)

1. Charmandari E, Tsigos C, Chrousos G. Endocrinology of stress responses. Ann Rev Physiol 2005;67:259-84
2. Stolte EH, Verburg Van Kemenade BML, et al. Evolution of glucocorticoid receptors with different glucocorticoid sensitivity. J Endocrinol 2006;190:17-28
3. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effect of hormone of adrenal cortex (17-hydroxy-11-dehydrocorticosterone compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis: preliminary report. Proc Staff Meet Mayo Clin 1949;24:181-97
4. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Med Intern 1950;85:545-666
5. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43
6. Miner JN, Hong MH, Negro-Vilar A. New and improved glucocorticoid receptor ligands. Expert Opin Investig Drugs 2005;14:1527-45
7. Bodor N, Buchwald P. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 2006;12:3241-60
8. O'Connell EJ. Review of the unique properties of budesonide. Clin Ther 2003;25:C42-60
9. Welker P, Lippert U, Nurnberg W, et al. Glucocorticoid-induced modulation of cytokine secretion from normal and leukemic human myelomonocytic cells. Int Arch Allergy Immunol 1996;109:110-5
10. Günther C, Kecskes A, Staks T, Täuber U. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan® lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol Appl Skin Physiol 1998;11:35-42
11. Reichardt HM, Schütz G. GC-signaling: multiple variations of a common scheme. Mol Cell Endocrinol 1998;146:1-6
12. Wárnmark A, Treuter E, Wright APM, Gustafson JA. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol 2003;17:1901-9
13. Cairns BR, Levinson RS, Yamamoto KR, Kornberg RD. Essential role of Swp73p in the function of yeast Swi/Snf complex. Genes Dev 1996;10:2131-44
14. Yoshinaga SK, Peterson CL, Herskowitz I, Yamamoto KR. Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science 1992;258:1598-604
15. Pratt WB. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Ann Rev Pharmacol Toxicol 1997;37:297-326
16. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997;18:306-60
17. Buchner J. Hsp90 & Co.: a holding for folding. Trends Biol Sci 1999;24:136-41
18. Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 2007;275:2-12
19. Yamamoto KR, Darimont BD, Wagner RL, niguez-Lluhija A. Building transcriptional regulatory complexes: signals and surfaces. Cold Spring Harb Syrnp Quant Biol 1998;63:587-98
20. Chinenov Y, Rogatsky I. Glucocorticoids and the innate immune system: crosstalk with the Toll-like receptor signalling network. Mol Cell Endocrinol 2007;275:30-42
21. Heck S, Kuilmann M, Gast A, et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription of AP-1. EMBO J 1994;13:4087-95
22. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-41
23. Rogatsky I, Wang JC, Derynck MK, et al. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc Natl. Acad Sci USA 2003;100:13845-50
24. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996;383:726-8
25. Lerner L, Henriksen MA, Zhang X, Darnell JE Jr. STAT3-dependent enhancosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev 2003;17:2564-77
26. Rogatsky I, Ivashkiv LB. Glucocorticoid modulation of cytokine signalling. Tissue Antigens 2006;68:1-12
27. Philips A, Maira M, Mullick A, et al. Antagonism between Nurr77 and glucocorticoid receptor for control of transcription. Mol Cell Biol 1997;17:5952-9
28. Meyer T, Gustafsson JA, Carlstedt-Duke J. Glucocorticoid-dependent transcriptional repression of the osteocalcin gene by competitive binding at the TATA box. DNA Cell Biol 1997;16:919-27
29. Tuckermann JP, Reichardt HM, Arribas R, et al. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 1999;147:1365-70
30. Reily MM, Pantoja C, Hu X, et al. The GRIP 1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J 2006;25:108-17
31. Ogawa S, Lozach J, Benner C, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005;122:707-21
32. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol 2007;275:13-29
33. Feige JN, Auwerx J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol 2007;17:292-301
34. Xu J, O'Malley BW. Molecular mechanisms and cellular biology of the steroid receptor coactivator (SRC) family in steroid receptor function. Rev Endocr Metab Disord 2002;3:185-92
35. Rogatsky I, Zarember KA, Yamamoto KR. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 2001;20:6071-83
36. Reichardt HM, Tuckermann JP, Göttlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001;20:7168-73
37. Young JD, Lawrence AJ, Maclean AG, et al. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 1999;5:1424-7
38. Berrebi D, Bruscoli S, Cohen N, et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 2003;101:729-38
39. Hamdi H, Godot V, Maillot MC, et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood 2007;110:211-9
40. Calandra T, Bernhagen J, Metz CN, et al. MW as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71
41. Mizuno H, Uemura K, Moriyama A, et al. Glucocorticoid-induced expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells. Brain Res 1997;764:256-64
42. Lai WS, Caraballo E, Sturm JR, et al. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 1999;19:4311-23
43. Smoak K, Cidlowski JA. Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signalling. Mol Cell Biol 2006;26:9126-35
44. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 2007;72:799-809
45. Tronche F, Opherk C, Moriggl R, et al. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev 2004;18:492-7
46. Tuckermann J, Schilling AF, Kleyman A, et al. Glucocorticoid induced osteoporosis requires the glucocorticoid receptor in osteoblasts and does not depend on DNA binding of the receptor. Abstract, Symposium on Nuclear Receptors: Steroid Sisters, Keystone; 2006
47. Adams M, Meijer OC, Wang J, et al. Homodimerization of the glucocorticoid receptor is not essential for response element binding: activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol Endocrinol 2003;17:2583-92
48. Schäcke H, Schottelius A, Döcke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101:227-32
49. Coghlan MJ, Jacobson PB, Lane B, et al. A novel anti-inflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 2003;17:860-9
50. Mohler ML, He Y, Wu Z, et al. Dissocated non-steroidal glucocorticoids: tuning out untoward effects. Expert Opin Ther Patents 2007;17:37-58
51. Braddock M. Advances in anti-inflammatory therapeutics. Expert Opin Investig Drugs 2007;16:257-61
52. Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA 2007;104:19244-9
53. Bayer Schering Pharma AG. 1-Amino-2-oxy-substituted tetrahydronaphthalene derivatives, methods for the production thereof, and their use as antiphlogistics. WO2005034939 (2005)
54. Bayer Schering Pharma AG. Tetrahydronaphthalene derivatives, methods for their production and their use as anti-inflammatory agents. WO2006100100 (2006)
55. Bayer Schering Pharma AG. Tetrahydronaphthalene derivatives, methods for their production and use thereof as anti-inflammatory agents. WO2007104582 (2007)
56. Astrazeneca/Bayer Schering Pharma AG. Novel bicyclic sulfonamides for use as glucocorticoid receptor modulators in the treatment of inflammatory diseases. WO2007046747 (2007)
57. Marshall DR, Rodriguez G, Thomson DS, et al. α-Methyltryptamine sulphonamidederivatives as novel glucocorticoid receptor agonists. Bioorg Med Chem Lett 2007;17:315-9
58. Thomson DS. Identification and optimization of non-steroidal glucocorticoid receptor agonists. 233rd ACS National Meeting, Chicago; 2007. MEDI 217
59. Regan J, Lee TW, Zindell RM, et al. Quinol-4-ones as steroid A-ring mimetics in nonsteroidal dissociated glucocorticoid agonists. J Med Chem 2006;49:7887-96
60. Boehringer Ingelheim International GMBH. 1,1,1-Trifluoro-4-phenyl-4- methyl-2-(1H-pyrrolo[2,3,c]pyridine-2-ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes. WO2005030213 (2005)
61. Thomson DS. SCIharm, Edinburgh; 2006 (personal communication)
62. Song JJ, Tan Z, Xu J, et al. Practical stereoselective synthesis of an α-trifluoromethyl-α-alkyl epoxide via a diastereoselective trifluoromethylation reaction. J Org Chem 2007;72:292-4
63. Harcken C, Ward Y, Thomson D, Riether D. A general and efficient synthesis of azaindoles and diazaindoles. Synlett 2005;20:3121-5
64. Boehringer Ingelheim International GMBH. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. WO2006135826 (2006)
65. Bristol-Myers Squibb CO. Modulators of the glucocorticoid receptor, AP-1, and/or NFκB activity and use thereof. WO2006138373 (2006)
66. Thompson CF, Quraishi N, Ali A, et al. Novel heterocyclic glucocorticoids: in vitro profile and in vivo efficacy. Bioorg Med Chem Lett 2005;15:2163-7
67. Shah N, Scanlan TS. Design and evaluation of novel nonsteroidal dissociating glucocorticoid receptor ligands. Bioorg Med Chem Lett 2004;14:5199-203
68. Bristol-Myers Squibb. Modulators of the glucocorticoid receptor, AP-1, and/or NFκB activity and use thereof. WO2006076702 (2006)
69. Bristol-Myers Squibb CO. Indane modulators of glucocorticoid receptor, AP-1, and/or NFκB activity and use thereof. WO2007073503 (2007)
70. Glaxo Group Ltd. Indazoles as glucocorticoid receptor ligands. WO2006108699 (2006)
71. Glaxo Group Ltd. Phenyl-pyrazole derivatives as non-steroidal glucocorticoid receptor ligands. WO2007000334 (2007)
72. Glaxo Group Ltd. Pyrazolo-pyrimidine derivatives as anti-inflammatory agents. WO2007054294 (2007)
73. Glaxo Group Ltd. Novel compounds. WO2007122165 (2007)
74. Clackers M, Coe DM, Demaine DA, et al. Non-steroidal glucocorticoid agonists: the discovery of asyl pyrazoles as A-ring mimetics. Bioorg Med Chem Lett 2007;17:4737-45
75. Barker M, Clackers M, Copley R, et al. Dissociated nonsteroidal glucocorticoid receptor modulators: discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. J Med Chem 2006;49:4216-31
76. Glaxo Group Ltd. Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators. US20070224130 (2007)
77. F. Hoffmann-La Roche AG. Propionamide compounds as antiinflammatory agents. WO2007065821 (2007)
78. F. Hoffmann-La Roche AG. Glucocorticoid receptor modulators as anti-inflammatory agents. WO2007065828 (2007)
79. Akzo Nobel NV. Non-steroidal compounds useful as glucocorticoid receptor modulators. WO2007025938 (2007)
80. Akzo Nobel NV. Non steroidal glucocorticoid receptor modulators. WO2006084917 (2006)
81. NV Organon And Pharmacopeia Drug Discovery, Inc. Compounds with medicinal effects due to interaction with the glucocorticoid receptor. WO2007071638 (2007)
82. Dainippon Sumitomo Pharma Co. Ltd. Novel fused pyrrole derivative. WO2007040166 (2007)
83. Santen Pharmaceutical Co. Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity. WO2007032556 (2007)